Published in Development on May 10, 2006
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A (2006) 4.66
Conditional deletion of Smad1 and Smad5 in somatic cells of male and female gonads leads to metastatic tumor development in mice. Mol Cell Biol (2007) 1.72
β-Catenin is essential for Müllerian duct regression during male sexual differentiation. Development (2011) 1.62
Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Proc Natl Acad Sci U S A (2008) 1.41
Cellular mechanisms of Müllerian duct formation in the mouse. Dev Biol (2007) 1.36
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci U S A (2012) 1.21
Functions of the type 1 BMP receptor Acvr1 (Alk2) in lens development: cell proliferation, terminal differentiation, and survival. Invest Ophthalmol Vis Sci (2008) 1.08
Functional redundancy of TGF-beta family type I receptors and receptor-Smads in mediating anti-Mullerian hormone-induced Mullerian duct regression in the mouse. Biol Reprod (2008) 1.05
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A (2006) 1.02
Cancer stem cells as targets for cancer therapy: selected cancers as examples. Arch Immunol Ther Exp (Warsz) (2008) 0.95
Endocrine disruptors in female reproductive tract development and carcinogenesis. Trends Endocrinol Metab (2009) 0.95
Normal and abnormal epithelial differentiation in the female reproductive tract. Differentiation (2011) 0.95
c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction. Endocrinology (2007) 0.92
Vitamin D alters genes involved in follicular development and steroidogenesis in human cumulus granulosa cells. J Clin Endocrinol Metab (2014) 0.91
Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines. Gynecol Oncol (2010) 0.90
Focal Mullerian duct retention in male mice with constitutively activated beta-catenin expression in the Mullerian duct mesenchyme. Proc Natl Acad Sci U S A (2010) 0.90
Cell migration and activated PI3K/AKT-directed elongation in the developing rat Müllerian duct. Dev Biol (2008) 0.87
Wilms' tumor protein Wt1 is an activator of the anti-Müllerian hormone receptor gene Amhr2. Mol Cell Biol (2007) 0.87
Molecular analysis of the beta-catenin gene in patients with the Mayer-Rokitansky-Küster-Hauser syndrome. J Assist Reprod Genet (2008) 0.84
siRNA as a tool for investigating organogenesis: The pitfalls and the promises. Organogenesis (2008) 0.84
The tumor suppressor gene Trp53 protects the mouse lens against posterior subcapsular cataracts and the BMP receptor Acvr1 acts as a tumor suppressor in the lens. Dis Model Mech (2011) 0.83
AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer. Proc Natl Acad Sci U S A (2015) 0.82
Molecular genetics of Müllerian duct formation, regression and differentiation. Sex Dev (2014) 0.81
Lhx1 is required in Müllerian duct epithelium for uterine development. Dev Biol (2014) 0.80
Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance. Protein Expr Purif (2009) 0.79
Contribution of Caudal Müllerian Duct Mesenchyme to Prostate Development. Stem Cells Dev (2016) 0.76
The TGF-β Family in the Reproductive Tract. Cold Spring Harb Perspect Biol (2017) 0.76
Partial Müllerian Duct Retention in Smad4 Conditional Mutant Male Mice. Int J Biol Sci (2016) 0.75
Induction of WNT inhibitory factor 1 expression by Müllerian inhibiting substance/antiMullerian hormone in the Müllerian duct mesenchyme is linked to Müllerian duct regression. Dev Biol (2013) 0.75
Detection of large-scale variation in the human genome. Nat Genet (2004) 49.18
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A (2006) 4.66
A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes. Proc Natl Acad Sci U S A (2008) 3.57
Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants. Nat Biotechnol (2011) 3.25
Sex determination and differentiation. N Engl J Med (2004) 3.07
ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet (2007) 2.77
Requirement of Bmpr1a for Müllerian duct regression during male sexual development. Nat Genet (2002) 2.75
Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril (2002) 2.10
Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. Dev Biol (2005) 2.07
Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nat Genet (2007) 1.85
HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci U S A (2009) 1.45
Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Proc Natl Acad Sci U S A (2008) 1.41
Dissecting spatio-temporal protein networks driving human heart development and related disorders. Mol Syst Biol (2010) 1.35
The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab (2002) 1.33
Constitutive WNT/beta-catenin signaling in murine Sertoli cells disrupts their differentiation and ability to support spermatogenesis. Biol Reprod (2009) 1.26
The immunophilin FKBP12: a molecular guardian of the TGF-beta family type I receptors. Front Biosci (2004) 1.25
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci U S A (2012) 1.21
Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci U S A (2010) 1.20
Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum Mol Genet (2010) 1.20
Propranolol as an alternative treatment option for pediatric lymphatic malformation. Tohoku J Exp Med (2013) 1.19
Adult mouse myometrial label-retaining cells divide in response to gonadotropin stimulation. Stem Cells (2007) 1.18
Management and long-term follow-up of patients with types III and IV laryngotracheoesophageal clefts. J Pediatr Surg (2005) 1.17
Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res (2002) 1.15
Mullerian inhibiting substance acts as a motor neuron survival factor in vitro. Proc Natl Acad Sci U S A (2005) 1.14
Small-angle scattering and the structure of ambient liquid water. Proc Natl Acad Sci U S A (2010) 1.13
MIS/AMH in the assessment of cryptorchidism and intersex conditions. Mol Cell Endocrinol (2003) 1.11
Chick pulmonary Wnt5a directs airway and vascular tubulogenesis. Development (2008) 1.10
Genetic and environmental risk factors in congenital heart disease functionally converge in protein networks driving heart development. Proc Natl Acad Sci U S A (2012) 1.08
Iris hypoplasia in mice that lack the alternatively spliced Pax6(5a) isoform. Proc Natl Acad Sci U S A (2002) 1.08
Persistent Mullerian duct syndrome caused by both a 27-bp deletion and a novel splice mutation in the MIS type II receptor gene. Birth Defects Res A Clin Mol Teratol (2003) 1.07
Genetic studies of the AMH/MIS signaling pathway for Müllerian duct regression. Mol Cell Endocrinol (2003) 1.07
Infants with Bochdalek diaphragmatic hernia: sibling precurrence and monozygotic twin discordance in a hospital-based malformation surveillance program. Am J Med Genet A (2005) 1.06
Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cells. Cell Cycle (2007) 1.04
Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res (2006) 1.02
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A (2006) 1.02
High dose intravenous methylprednisolone resolves esophageal stricture resistant to balloon dilatation with intralesional injection of dexamethasone. Pediatr Surg Int (2008) 1.02
Intersex genetic anomalies with malignant potential. Curr Opin Pediatr (2006) 1.01
Congenital diaphragmatic hernia candidate genes derived from embryonic transcriptomes. Proc Natl Acad Sci U S A (2012) 1.01
New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 1.00
Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance. Proc Natl Acad Sci U S A (2004) 0.99
Congenital diaphragmatic hernia (CDH) etiology as revealed by pathway genetics. Am J Med Genet C Semin Med Genet (2007) 0.99
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo. Proc Natl Acad Sci U S A (2002) 0.99
Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci U S A (2003) 0.98
Feedback inhibition of steroidogenic acute regulatory protein expression in vitro and in vivo by androgens. Endocrinology (2003) 0.98
Donnai-Barrow syndrome (DBS/FOAR) in a child with a homozygous LRP2 mutation due to complete chromosome 2 paternal isodisomy. Am J Med Genet A (2008) 0.96
MEK-1/2 inhibition reduces branching morphogenesis and causes mesenchymal cell apoptosis in fetal rat lungs. Am J Physiol Lung Cell Mol Physiol (2002) 0.96
Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers. Future Oncol (2010) 0.95
Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril (2005) 0.93
c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction. Endocrinology (2007) 0.92
Uterine leiomyomas exhibit fewer stem/progenitor cell characteristics when compared with corresponding normal myometrium. Reprod Sci (2009) 0.92
Cucurbitacin D isolated from Trichosanthes kirilowii induces apoptosis in human hepatocellular carcinoma cells in vitro. Int Immunopharmacol (2009) 0.91
Mesenchymal-to-epithelial transition contributes to endometrial regeneration following natural and artificial decidualization. Stem Cells Dev (2013) 0.91
Focal Mullerian duct retention in male mice with constitutively activated beta-catenin expression in the Mullerian duct mesenchyme. Proc Natl Acad Sci U S A (2010) 0.90
Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines. Gynecol Oncol (2010) 0.90
Characterization of the chromosome 1q41q42.12 region, and the candidate gene DISP1, in patients with CDH. Am J Med Genet A (2010) 0.90
Congenital diaphragmatic hernia interval on chromosome 8p23.1 characterized by genetics and protein interaction networks. Am J Med Genet A (2012) 0.89
Serum Müllerian Inhibiting Substance/anti-Müllerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology. Gynecol Oncol (2009) 0.88
Mullerian inhibiting substance: an update. Adv Exp Med Biol (2002) 0.88
Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor. J Endocrinol (2007) 0.88
Mullerian inhibiting substance promotes interferon gamma-induced gene expression and apoptosis in breast cancer cells. J Biol Chem (2003) 0.88
Cell migration and activated PI3K/AKT-directed elongation in the developing rat Müllerian duct. Dev Biol (2008) 0.87
Repeat STEP procedure to establish enteral nutrition in an infant with short bowel syndrome. Pediatr Surg Int (2009) 0.86
Congenital adrenal hyperplasia: surgical considerations required to repair a 46,XX patient raised as a boy. J Pediatr Surg (2003) 0.86
Mullerian-inhibiting substance induces Gro-beta expression in breast cancer cells through a nuclear factor-kappaB-dependent and Smad1-dependent mechanism. Cancer Res (2007) 0.85
Measurement of Mullerian inhibiting substance facilitates management of boys with microphallus and cryptorchidism. J Clin Endocrinol Metab (2002) 0.85
Acoustic radiation force impulse imaging for assessing graft fibrosis after pediatric living donor liver transplantation: a pilot study. Liver Transpl (2013) 0.85